FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1570337497> ?p ?o ?g. }

• W1570337497 endingPage "969" @default.
• W1570337497 startingPage "962" @default.
• W1570337497 abstract "The present trial investigated the efficacy and safety of dalteparin in the prevention of arterial thromboembolism after an acute anterior myocardial infarction (MI).Left ventricular (LV) thrombus formation is associated with increased risk of arterial embolism in patients with an acute MI. Thrombolytic and antiplatelet therapy do not prevent thrombus formation.A total of 776 patients were enrolled in a multicenter, randomized, double-blind, placebo-controlled trial of subcutaneous dalteparin (150 IU/kg body weight every 12 h during the hospital period). Thrombolytic therapy and aspirin were administered in 91.5% and 97.6% of patients, respectively. The primary study end point was the composite of thrombus formation diagnosed by echocardiography and arterial embolism on day 9 +/- 2.Of 517 patients with echocardiographic recordings available for end point analysis, thrombus formation or embolism, or both, was found in 59 (21.9%) of 270 patients (59 with thrombus, none with embolism) in the placebo group and 35 (14.2%) of 247 patients (34 with thrombus, 1 with embolism) in the dalteparin group (p = 0.03). The risk reduction of thrombus formation associated with dalteparin treatment was 0.63 (95% confidence interval 0.43 to 0.92, p = 0.02). Analyses of all randomized patients (388 in each group) revealed no significant difference between the placebo and dalteparin groups with respect to arterial embolism (6 vs. 5 patients), reinfarction (8 vs. 6 patients) and mortality rates (23 vs. 23 patients, p = NS for all). Dalteparin was associated with an increased risk of hemorrhage: major in 11 dalteparin group patients (2.9%) verus 1 placebo group patient (0.3%, p = 0.006); minor in 52 dalteparin group patients (14.8%) versus 8 placebo group patients (1.8%, p < 0.001).Dalteparin treatment significantly reduces LV thrombus formation in acute anterior MI but is associated with increased hemorrhagic risk." @default.
• W1570337497 created "2016-06-24" @default.
• W1570337497 creator A5018822907 @default.
• W1570337497 creator A5034139580 @default.
• W1570337497 creator A5069534990 @default.
• W1570337497 creator A5083340275 @default.
• W1570337497 date "1997-10-01" @default.
• W1570337497 modified "2023-10-12" @default.
• W1570337497 title "Randomized Trial of Low Molecular Weight Heparin (Dalteparin) in Prevention of Left Ventricular Thrombus Formation and Arterial Embolism After Acute Anterior Myocardial Infarction: The Fragmin in Acute Myocardial Infarction (FRAMI) Study 11This study was supported by grants from the Norwegian Council on Cardiovascular Diseases, Oslo, Norway and Pharmacia AB, Stockholm, Sweden." @default.
• W1570337497 cites W1527418628 @default.
• W1570337497 cites W1581187193 @default.
• W1570337497 cites W1786317249 @default.
• W1570337497 cites W1971590984 @default.
• W1570337497 cites W1972083038 @default.
• W1570337497 cites W1974614925 @default.
• W1570337497 cites W1976208297 @default.
• W1570337497 cites W1992652746 @default.
• W1570337497 cites W1998935735 @default.
• W1570337497 cites W2008293739 @default.
• W1570337497 cites W2009039478 @default.
• W1570337497 cites W2014056997 @default.
• W1570337497 cites W2017138612 @default.
• W1570337497 cites W2021885279 @default.
• W1570337497 cites W2033724005 @default.
• W1570337497 cites W2064799100 @default.
• W1570337497 cites W2066556905 @default.
• W1570337497 cites W2069662916 @default.
• W1570337497 cites W2071239372 @default.
• W1570337497 cites W2075224801 @default.
• W1570337497 cites W2080525953 @default.
• W1570337497 cites W2083180810 @default.
• W1570337497 cites W2086108683 @default.
• W1570337497 cites W2121284791 @default.
• W1570337497 cites W2126791223 @default.
• W1570337497 cites W2158764362 @default.
• W1570337497 cites W2329761741 @default.
• W1570337497 cites W2337749843 @default.
• W1570337497 cites W3170680033 @default.
• W1570337497 cites W4251417417 @default.
• W1570337497 cites W84205322 @default.
• W1570337497 doi "https://doi.org/10.1016/s0735-1097(97)00258-1" @default.
• W1570337497 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/9316525" @default.
• W1570337497 hasPublicationYear "1997" @default.
• W1570337497 type Work @default.
• W1570337497 sameAs 1570337497 @default.
• W1570337497 citedByCount "115" @default.
• W1570337497 countsByYear W15703374972012 @default.
• W1570337497 countsByYear W15703374972013 @default.
• W1570337497 countsByYear W15703374972014 @default.
• W1570337497 countsByYear W15703374972015 @default.
• W1570337497 countsByYear W15703374972016 @default.
• W1570337497 countsByYear W15703374972017 @default.
• W1570337497 countsByYear W15703374972019 @default.
• W1570337497 countsByYear W15703374972020 @default.
• W1570337497 countsByYear W15703374972021 @default.
• W1570337497 countsByYear W15703374972022 @default.
• W1570337497 countsByYear W15703374972023 @default.
• W1570337497 crossrefType "journal-article" @default.
• W1570337497 hasAuthorship W1570337497A5018822907 @default.
• W1570337497 hasAuthorship W1570337497A5034139580 @default.
• W1570337497 hasAuthorship W1570337497A5069534990 @default.
• W1570337497 hasAuthorship W1570337497A5083340275 @default.
• W1570337497 hasBestOaLocation W15703374971 @default.
• W1570337497 hasConcept C126322002 @default.
• W1570337497 hasConcept C142724271 @default.
• W1570337497 hasConcept C164705383 @default.
• W1570337497 hasConcept C168563851 @default.
• W1570337497 hasConcept C203092338 @default.
• W1570337497 hasConcept C204787440 @default.
• W1570337497 hasConcept C27081682 @default.
• W1570337497 hasConcept C2776884760 @default.
• W1570337497 hasConcept C2777185221 @default.
• W1570337497 hasConcept C2777557582 @default.
• W1570337497 hasConcept C2777628954 @default.
• W1570337497 hasConcept C2777650959 @default.
• W1570337497 hasConcept C2779208316 @default.
• W1570337497 hasConcept C2780868729 @default.
• W1570337497 hasConcept C2781362458 @default.
• W1570337497 hasConcept C42219234 @default.
• W1570337497 hasConcept C500558357 @default.
• W1570337497 hasConcept C71924100 @default.
• W1570337497 hasConceptScore W1570337497C126322002 @default.
• W1570337497 hasConceptScore W1570337497C142724271 @default.
• W1570337497 hasConceptScore W1570337497C164705383 @default.
• W1570337497 hasConceptScore W1570337497C168563851 @default.
• W1570337497 hasConceptScore W1570337497C203092338 @default.
• W1570337497 hasConceptScore W1570337497C204787440 @default.
• W1570337497 hasConceptScore W1570337497C27081682 @default.
• W1570337497 hasConceptScore W1570337497C2776884760 @default.
• W1570337497 hasConceptScore W1570337497C2777185221 @default.
• W1570337497 hasConceptScore W1570337497C2777557582 @default.
• W1570337497 hasConceptScore W1570337497C2777628954 @default.
• W1570337497 hasConceptScore W1570337497C2777650959 @default.
• W1570337497 hasConceptScore W1570337497C2779208316 @default.
• W1570337497 hasConceptScore W1570337497C2780868729 @default.
• W1570337497 hasConceptScore W1570337497C2781362458 @default.
• W1570337497 hasConceptScore W1570337497C42219234 @default.
• W1570337497 hasConceptScore W1570337497C500558357 @default.

• next